Rafael Gual, general director of CANIFARMA, the chamber that brings together multinational and local drug manufacturers, details how the organization is currently intensifying its efforts to ensure the pharmaceutical industry as a whole is officially recognized as a strategic Mexican industry by both the Ministries of Health and Economy, while also providing an overview of the main trends and dynamics that are currently impacting the Mexican industry.
When we met with you in 2014, you highlighted that “the pharmaceutical industry in Mexico was undergoing a rapid transformation, while offering interesting opportunities to international investors.” How has the sector evolved since our last meeting?
Our sector goes beyond pharmaceutical companies and must be considered an entire eco-system comprising a variety of different providers and suppliers – in the same fashion as the automotive sector.
